Monte Rosa Therapeutics Inc [GLUE] stock is trading at $4.01, down -3.61%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GLUE shares have gain 8.38% over the last week, with a monthly amount drifted -16.63%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Monte Rosa Therapeutics Inc [NASDAQ: GLUE] stock has seen the most recent analyst activity on December 19, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $11 from $14. Previously, Wedbush started tracking the stock with Outperform rating on February 15, 2024, and set its price target to $11. On January 03, 2023, upgrade upgraded it’s rating to Overweight but maintained its price target of $18 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $22 on October 13, 2022. Jefferies initiated its recommendation with a Buy and recommended $20 as its price target on August 15, 2022. Credit Suisse started tracking with a Neutral rating for this stock on April 28, 2022, and assigned it a price target of $19. In a note dated February 10, 2022, Wells Fargo initiated an Equal Weight rating and provided a target price of $19 on this stock.
Monte Rosa Therapeutics Inc [GLUE] stock has fluctuated between $3.21 and $12.40 over the past year. Monte Rosa Therapeutics Inc [NASDAQ: GLUE] shares were valued at $4.01 at the most recent close of the market.
Analyzing the GLUE fundamentals
Monte Rosa Therapeutics Inc [NASDAQ:GLUE] reported sales of 159.49M for the trailing twelve months, which represents a growth of 7882.05%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.01%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.03 and Total Capital is -0.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Monte Rosa Therapeutics Inc’s Current Ratio is 5.61. Also, the Quick Ratio is 5.61, while the Cash Ratio stands at 1.33. Considering the valuation of this stock, the price to sales ratio is 1.55, the price to book ratio is 0.90 and price to earnings (TTM) ratio is 59.67.
Transactions by insiders
Recent insider trading involved Leo Chandra P., Director, that happened on Mar 24 ’25 when 10000.0 shares were purchased. 10% Owner, Versant Venture Capital VI, L. completed a deal on Oct 28 ’24 to sell 89990.0 shares. Meanwhile, 10% Owner Versant Venture Capital VI, L. sold 67905.0 shares on Oct 29 ’24.
